Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
by Readline Biotech Healthy Aging/Skin Health by Zhejiang Hisun Pharmaceutical Co.,Ltd
AOD-9604 will not produce the 20-50 pound transformations that GLP-1 agonists produce
The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible
See Peptide Half-Life Explained
US$ 22.95
US$ 20.85
US$ 25.86
US$ 24.10
US$ 22.68
US$ 22.26
US$ 27.73
US$ 20.60
US$ 20.21
US$ 27.69
US$ 28.80
US$ 20.53
